Latest Headlines

Latest Headlines

NICE likes Lundbeck's alcohol-addiction drug Selincro

Lundbeck has gotten a recommendation from the U.K. cost watchdog for its alcohol-addiction drug Selincro. It is estimated that there are about 600,000 potential users in the U.K. A final decision is slated for fall.

Lundbeck makes $658M bid for Chelsea, gaining once-rejected dizziness drug Northera

One day after announcing a drop in quarterly sales and profits, Danish drugmaker Lundbeck said it will pick up Chelsea Therapeutics for cash and contingent value rights in a deal worth up to $658 million.

Lundbeck is buying Chelsea for $658M, with a just-in-case clause

After months of speculation and Wall Street tremulance, Chelsea Therapeutics finally got its buyout deal: Lundbeck has agreed to pick up the biotech for as much as $658 million, provided its banner drug can come through on the sales front.

Despite pomp and circumstance, 2014's looking short on blockbusters

Biopharma's long-heralded return to R&D ROI may come up short this year, according to EvaluatePharma, and the next class of approved drugs features fewer blockbusters in waiting than in any of the previous four years.

Think fast: A new cognition study could add $350M to Lundbeck's Brintellix sales

To successfully launch a new drug in a crowded market, you need a way to differentiate your product. Lundbeck may have found just that, in the form of a study showing that its new antidepressant, Brintellix, helped patients think, concentrate and remember.

Lundbeck teams with Otsuka on Alzheimer's vaccine development

The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year.

Alzheimer's investigators launch big PhIII program for Lundbeck, Otsuka drug

Lundbeck and its partners at Otsuka are embarking on a lengthy Phase III journey in search of solid evidence that their Alzheimer's drug Lu AE58054 in combination with donepezil can improve the swiftly eroding cognitive functions of Alzheimer's patients.

Shutdown looming, FDA approves new depression drug from Lundbeck, Takeda

Regulators at the FDA stamped an approval on Brintellix, a new therapy to treat major depression from Lundbeck and Takeda, just hours before the government prepared to hunker down in a partial shutdown.

FDA approves Lundbeck, Takeda antidepressant Brintellix

Danish drugmaker Lundbeck has been hiring more than 200 sales reps in the U.S. in anticipation of the FDA approval of the blockbuster antidepressant Brintellix. Well, now they have something to sell.

Lundbeck's cost-saving reorg plan to claim up to 200 jobs

Supply-chain simplification and new procurement processes are also part of the plan.